IDOGEN.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 liep. 2023 @ 17:26):

Stats
Dzisiejszy wolumen	1.13M
Średni wolumen	0.00
Kapitalizacja rynkowa	12.79M
EPS	SEK-0.0727 ( 2023-05-09 )
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-0.320
ATR14	SEK0.0520 (43.15%)

Wolumen Korelacja

Długi: 0.58 (weak)

Krótki: 0.25 (neutral)

Signal:(48.38) Neutral

Idogen AB (publ) Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Idogen AB (publ) Korelacja - Waluta/Towar

-0.07
( neutral )

-0.08
( neutral )

0.00
( neutral )

0.05
( neutral )

-0.40
( neutral )

-0.08
( neutral )

Idogen AB (publ) Finanse

Annual	2022
Przychody:	SEK0
Zysk brutto:	SEK0 (0.00 %)
EPS:	SEK-0.760

FY	2022
Przychody:	SEK0
Zysk brutto:	SEK0 (0.00 %)
EPS:	SEK-0.760

FY	2021
Przychody:	SEK0.00
Zysk brutto:	SEK0.00 (0.00 %)
EPS:	SEK-1.699

FY	2020
Przychody:	SEK0.00
Zysk brutto:	SEK0.00 (0.00 %)
EPS:	SEK-3.32

Financial Reports:

No articles found.

Idogen AB (publ)

Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, and the body's own cells or tissues in Sweden. The company's advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection primarily kidney transplantation; and IDO AID for the treatment of autoimmune diseases. The company was incorporated in 2008 and is headquartered in Lund, Sweden.